OncRef

Clinical Trial: NCT05186974

Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 2

Lead Sponsor:Gilead Sciences
Information Provided By:Gilead Sciences
Last Update Posted:2026-09-11

Study Overview

Brief Summary

The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy (SG), and its dosing in combination with pembrolizumab or pembrolizumab and a platinum agent (carboplatin or cisplatin), in participants with advanced or metastatic (cancer that has spread) non-small-cell lung cancer (NSCLC).

Official Title

An Open-label, Multicenter, Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations

Conditions

Non-small Cell Lung Cancer

Intervention / Treatment

  • Drug: Sacituzumab Govitecan-hziy (SG)
  • Drug: Pembrolizumab
  • Drug: Carboplatin
  • Drug: Cisplatin

Other Study ID Numbers

  • GS-US-576-6220
  • 2021-004280-27
  • KEYNOTE-D15
  • MK-3475-D15
  • 2024-513225-23

Start Date (Actual)

2022-05-30

Primary Completion Date (Estimated)

2027-03

Study Completion Date (Estimated)

2027-03

Enrollment (Actual)

193

Study Type

Interventional

Phase

Phase 2